Mutant Prevention Concentration as a Measure of Fluoroquinolone Potency against Mycobacteria
Open Access
- 1 December 2000
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 44 (12) , 3337-3343
- https://doi.org/10.1128/aac.44.12.3337-3343.2000
Abstract
Mutant prevention concentration (MPC) has been proposed as a new measure of antibiotic potency by which the ability to restrict selection of resistant mutants is evaluated. To determine whether MPC provides potency information unavailable from the more customary measurement of the MIC, 18 fluoroquinolones were examined for their ability to block the growth of Mycobacterium smegmatis and to select resistant mutants from wild-type populations. Both MPC and MIC were affected by changes in the moiety at the fluoroquinolone C-8 position and in alkyl groups attached to the C-7 piperazinyl ring. When eight resistant mutants, altered in the gyrase A protein, were tested with fluoroquinolones having either a methoxy or a hydrogen at the C-8 position, the MIC for the most resistant mutant correlated better with the MPC than did the MIC for wild-type cells. For C-8-fluorine derivatives, which were generally less active than the C-8-methoxy compounds but which were more active than C-8-hydrogen derivatives, the MICs for both the mutant and the wild type correlated well with the MPCs. Thus, measurement of the MICs for wild-type cells can reflect the ability of a quinolone to restrict the selection of resistance, but often it does not. With the present series of compounds, the most potent contained a C-8-methoxy and a small group attached to the C-7 ring.Keywords
This publication has 12 references indexed in Scilit:
- Mutant Prevention Concentration as a Measure of Antibiotic Potency: Studies with Clinical Isolates of Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2000
- Selection of Antibiotic?Resistant Bacterial Mutants: Allelic Diversity among Fluoroquinolone?Resistant MutationsThe Journal of Infectious Diseases, 2000
- Effect of Fluoroquinolone Concentration on Selection of Resistant Mutants of Mycobacterium bovis BCG and Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1999
- Fluoroquinolone Action against Clinical Isolates of Mycobacterium tuberculosis : Effects of a C-8 Methoxyl Group on Survival in Liquid Media and in Human MacrophagesAntimicrobial Agents and Chemotherapy, 1999
- Fluoroquinolone Action against Mycobacteria: Effects of C-8 Substituents on Growth, Survival, and ResistanceAntimicrobial Agents and Chemotherapy, 1998
- Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequenceNature, 1998
- Fluoroquinolone Resistance Associated with Specific Gyrase Mutations in Clinical Isolates of Multidrug-Resistant Mycobacterium tuberculosisThe Journal of Infectious Diseases, 1996
- Emergence of fluoroquinolone-resistant tuberculosis in New York CityThe Lancet, 1995
- Novel gyrA point mutation in a strain of Escherichia coli resistant to fluoroquinolones but not to nalidixic acidAntimicrobial Agents and Chemotherapy, 1993
- [25] Genetic systems for mycobacteriaPublished by Elsevier ,1991